ライフサイエンスコーパス: gadodiamide

1 with 3D MR DSA after the bolus injection of gadodiamide.

2 rates of physiologic reactions compared with gadodiamide.

3 patients in the contrast group had received gadodiamide.

4 2.1; P < .001) administration compared with gadodiamide.

5 sed to gadobenate dimeglumine in addition to gadodiamide.

6 ed to transendocardially inject a mixture of gadodiamide (0.05 mol/L) plus Evans blue dye (3%).

7 A high concentration of gadodiamide (0.5 mol/L) was used to demarcate the border

8 A single dose of gadodiamide (0.6 mmol/kg) resulted in rapid cerebrospina

9 .6 or 2.5 mmol per kilogram of body weight), gadodiamide (0.6 or 2.5 mmol/kg), or saline daily for 20

10 doterate, 9.2 [1.2]; gadoteridol, 9.9 [1.3]; gadodiamide, 10.5 [1.2]) or 5 weeks (saline, 19.7 [1.4];

11 terate, 14.3 [1.6]; gadoteridol, 22.2 [1.8]; gadodiamide, 17.9 [1.4]).

12 tions of either gadopiclenol, gadobutrol, or gadodiamide (2.4 mmol of gadolinium per kilogram of body

13 trations in the cerebellum were 3.38 nmol/g (gadodiamide), 2.13 nmol/g (gadopentetate dimeglumine), a

14 bined with only 15% washout after 12 months (gadodiamide, 2.25 nmol/g) and with gadolinium detected b

15 centrations after 1 month in the cerebellum (gadodiamide, 2.65 nmol/g; P < .001 vs both macrocyclics)

16 In vitro, the attenuation of undiluted gadodiamide (3,069 HU) was equivalent to that of ioverso

17 0.6% (DeltaR1 = 0.069 second(-1) +/- 0.018); gadodiamide, 5.4% (DeltaR1 = 0.055 second(-1) +/- 0.019)

18 ll 13 rats underwent 11.75-T MR imaging with gadodiamide (60 muL) 13 days after tumor implantation.

19 a total of 281 945 GBCA injections (140 645 gadodiamide, 94 109 gadobutrol, 39 138 gadobenate, and 8

20 In the cerebellum, the amount of intact gadodiamide accounts for 18.2% +/- 10.6 of the total gad

21 amide dose, renal function, and time between gadodiamide administration and phlebotomy.

22 Gadodiamide administration causes spurious hypocalcemia,

23 nges in serum calcium measurements following gadodiamide administration in 1,049 MR imaging examinati

24 inium retention in skin following formulated gadodiamide administration was located to the collagen f

25 calcium measurements up to 4(1/2) days after gadodiamide administration.

26 olinium skin concentrations were highest for gadodiamide after 5 days (16.0 nmol/g [1.1]) and 5 weeks

27 iron, as opposed to those animals exposed to gadodiamide alone; this experiment suggests that great c

28 The mean fDV of both tracers (gadodiamide and (99m)Tc-DTPA) in normal myocardium was 1

29 ed 48 hours after bevacizumab treatment with gadodiamide and 72 hours after treatment with ferumoxyto

30 Rats treated with gadodiamide and both Epo and intravenous iron (group D)

31 r-Wistar rats: group A, gadodiamide only; B, gadodiamide and Epo; C, gadodiamide and intravenous iron

32 ollowing administration of the linear agents gadodiamide and gadobenate dimeglumine compared with the

33 ol, and gadoterate meglumine), linear GBCAs (gadodiamide and gadobenate dimeglumine), or saline.

34 rodent femur following the administration of gadodiamide and gadobutrol at three different time point

35 Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence o

36 the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount o

37 The mean total gadolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 mu

38 gadodiamide only; B, gadodiamide and Epo; C, gadodiamide and intravenous iron; and D, gadodiamide, Ep

39 uation measurements of multiple dilutions of gadodiamide and ioversol were compared.

40 agnosis, all 13 patients had been exposed to gadodiamide and one had been exposed to gadobenate dimeg

41 r group) included low-dosage and high-dosage gadodiamide and osmolality-matched saline controls.

42 DSC MR imaging with gadodiamide and without preload showed low rCBV (</= 1.7

43 underwent DCE MR imaging after injection of gadodiamide, and gadolinium concentration-time curves we

44 by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentr

45 iminated within 5 weeks compared with linear gadodiamide, and intact macrocyclic GBCA was detected in

46 Gadodiamide appears to be a safe and useful intraarteria

47 th air as the contrast material) or T1 (with gadodiamide as the contrast material).

48 Eleven mice received gadodiamide before XFM.

49 Delivery of the gadodiamide-blue dye mixture and the consequences of the

50 to visualize the myocardial delivery of the gadodiamide-blue dye mixture.

51 Injection of gadodiamide caused a significant (P <.05) decrease in th

52 Gadoversetamide and gadodiamide caused a transient artifact in measurement o

53 A high concentration of gadodiamide caused signal intensity loss around the gado

54 Findings were correlated with first-pass gadodiamide contrast magnetic resonance imaging (MRI) in

55 Intravenous gadodiamide contrast was administered to define EOM tend

56 ulleys were directly imaged with intravenous gadodiamide contrast.

57 s after dosing with up to 20 repeat doses of gadodiamide (cumulative dose, 12 mmol per kilogram of bo

58 serum creatinine level (r = 0.39, P <.001), gadodiamide dose (r = 0.37, P <.001), and time between g

59 ormed in these patients were correlated with gadodiamide dose, renal function, and time between gadod

60 in the rat brain up to 1-year after repeated gadodiamide dosing and tissue retention kinetics after a

61 in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in G

62 Gadodiamide-enhanced angiograms appeared to be better th

63 Gadodiamide-enhanced angiograms were compared with CO2-e

64 Following 42 gadodiamide-enhanced examinations, serum calcium measure

65 f NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44,224 p

66 serum calcium data obtained before and after gadodiamide-enhanced MR imaging were identified.

67 ups: Group 1 included patients who underwent gadodiamide-enhanced MR imaging, and group 2 included pa

68 GP:TH and DN:MCP is associated with multiple gadodiamide-enhanced studies but not with gadobenate dim

69 een obtained with a 1.5-T MR unit by using a gadodiamide-enhanced T1-weighted spoiled gradient-recall

70 anges were more marked in animals exposed to gadodiamide, Epo, and intravenous iron, as opposed to th

71 C, gadodiamide and intravenous iron; and D, gadodiamide, Epo, and intravenous iron.

72 ssues from the four neuroanatomic regions of gadodiamide-exposed patients contained 0.1-19.4 mug of g

73 anical stimuli (P < .001) was observed after gadodiamide exposure in rats but not after gadoterate me

74 tes of allergic-like reactions compared with gadodiamide (gadobenate: odds ratio [OR], 3.9 [95% confi

75 80 human equivalent doses) of various GBCAs (gadodiamide, gadobenate, gadopentetate, gadoxetate, gado

76 as largely cleared from the CSF and serum of gadodiamide-, gadobenate-, gadoterate-, and gadobutrol-e

77 and administered gadobenate, gadopentetate, gadodiamide, gadobutrol (2.4 mmol/kg per week for 5 week

78 ompare reaction rates between the four GBCAs gadodiamide, gadobutrol, gadobenate dimeglumine, and gad

79 eived eight intravenous injections of either gadodiamide, gadobutrol, gadoterate, gadoteridol (8 x 0.

80 hy rats were repeatedly injected with either gadodiamide, gadobutrol, or saline solution and were kil

81 als and Methods Rats received a linear GBCA (gadodiamide, gadopentetate dimeglumine, gadobenate dimeg

82 ses of gadoversetamide; 1.0-mmol/kg doses of gadodiamide, gadopentetate, and gadoteridol; and a 6-mL/

83 There were insufficient analyzable data for gadodiamide, gadoversetamide, and gadopentetate.

84 The linear gadolinium contrast agents (gadodiamide, gadoversetamide, gadopentetate dimeglumine,

85 y the soluble paramagnetic relaxation agent, gadodiamide (Gd(DTPA-BMA)).

86 est gadolinium retention was observed in the gadodiamide group (concentration, 97-200 nmol . g(-1)),

87 The nonionic linear chelate gadodiamide had the lowest rate of reactions, at 1.5 (95

88 62% for basal ganglia, 70% for dentate) and gadodiamide having no substantial clearance.

89 events with use of the nonionic linear GBCA gadodiamide in comparison with those of ionic linear or

90 diffusion rates for Gd(3)N@C(80) relative to gadodiamide in live normal rat brain tissue.

91 13 mmol/L of Gd(3)N@C(80) and 0.50 mmol/L of gadodiamide in live normal rat brain.

92 Formulated gadodiamide increased dermal cell count, dermal thicknes

93 Omniscan and gadodiamide induced strong TLR4- and TLR7-mediated repor

94 ium per gram of tissue (95% CI: 6.2, 7.0) in gadodiamide-injected rats; a significant positive dose-s

95 The fDVs of gadodiamide injection and (99m)Tc-DTPA were measured and

96 e dose (r = 0.37, P <.001), and time between gadodiamide injection and phlebotomy (r = -0.28, P <.001

97 ows were injected with a solution containing gadodiamide, iodinated contrast agent, and gelatin.

98 Gadodiamide led to significantly higher gadolinium conce

99 Gadodiamide (linear contrast agent) but not gadoterate m

100 intravenous administration of 0.2 mmol/kg of gadodiamide, MDE-MRI was obtained.

101 15, mice underwent MRI at 9.4 T and received gadodiamide, MPO-Gd, or CLIO-NPs.

102 with documented exposure to GBCAs including gadodiamide (n = 307), gadopentetate dimeglumine (n = 49

103 Gadolinium-based contrast agents, formulated gadodiamide (n = 9) and gadoterate meglumine (n = 11), w

104 st or Gadavist, Bayer; macrocyclic GBCA) and gadodiamide (Omniscan, GE Healthcare; linear GBCA) over

105 = .004) compared with the rate treated with gadodiamide only (group A).

106 our groups of Hannover-Wistar rats: group A, gadodiamide only; B, gadodiamide and Epo; C, gadodiamide

107 tes of allergic-like reactions compared with gadodiamide or gadoterate, and gadoterate, gadobenate, a

108 MS) mapping after gadobenate, gadopentetate, gadodiamide, or gadobutrol administration.

109 urements after administration of 0.1 mmol of gadodiamide per kilogram of body weight were greater in

110 administration was dependent on the dose of gadodiamide preload, whereas the magnitude of rCBV decre

111 Formulated gadodiamide produced a 40-fold greater increase in gadol

112 higher than that for commercial agents (eg, gadodiamide); r1 values of 102, 143, and 32 L . mmol(-1)

113 Use of high-risk GBCAs, such as formulated gadodiamide, should be avoided in patients with renal di

114 Gadodiamide showed a significant increase in DN:MCP and

115 or gadopentetate, whereas rats treated with gadodiamide showed gadolinium-related DeltaR1 in caudate

116 Omniscan and gadodiamide signaling via TLRs 4 and 7 resulted in incre

117 r administration of more than 0.2 mmol/kg of gadodiamide, spurious calcium measurement decreases were

118 fore and after intravenous administration of gadodiamide), the pigs were observed for 7 days and foll

119 ared with reference Gd2O3 and contrast agent Gadodiamide, the features in the RIXS spectra of all met

120 In rats treated with gadodiamide, the largest part of gadolinium retained in

121 Following the switch from gadodiamide to gadobenate dimeglumine and gadopentetate

122 otein associations that impede the access of gadodiamide to the residues of the interaction surface.

123 renal interventions were performed by using gadodiamide (total dose, 0.3 mmol/kg) and CO2 as intraar

124 e healthy rat brain, markedly differing from gadodiamide up to 12 months after the last injection.

125 hough it is considerably less than that with gadodiamide use.

126 related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studi

127 High-dose gadodiamide was administered, 2.5 mmol per kilogram of b

128 Gadodiamide was the only agent used in the preadoption p

129 Although gadodiamide was used as a proof of concept model for GBC

130 Gadodiamide was used at University of North Carolina at

131 SF was much greater at the two centers where gadodiamide was used than at the two centers where gadop

132 In three pigs, 50-mL boluses of undiluted gadodiamide were injected intravenously at 2 mL/sec, and

133 resent in the brain after repeat dosing with gadodiamide, which is partially cleared over 20 weeks wi

134 s treated with gadobenate, gadopentetate, or gadodiamide, with the average gadolinium concentration o

135 ed gadolinium was intact soluble GBCA, while gadodiamide yielded both soluble and insoluble gadoliniu